Cutler Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-73,300
| Closed | -$220K | – | 6532 |
|
|
2021
Q3 | $220K | Buy |
+73,300
| New | +$9.59M | 0.01% | 1293 |
|
|
2020
Q3 | – | Sell |
-19,400
| Closed | -$128K | – | 5467 |
|
|
2020
Q2 | $128K | Buy |
19,400
+15,700
| +424% | +$1.51M | 0.01% | 1150 |
|
|
2020
Q1 | $18K | Buy |
+3,700
| New | +$288K | ﹤0.01% | 2383 |
|
|
2018
Q3 | – | Sell |
-16,000
| Closed | -$15K | – | 4947 |
|
|
2018
Q2 | $15K | Buy |
+16,000
| New | +$583K | ﹤0.01% | 2412 |
|
|
2017
Q4 | – | Sell |
-7,100
| Closed | -$4K | – | 6307 |
|
|
2017
Q3 | $4K | Sell |
7,100
-2,000
| -22% | -$69.4K | ﹤0.01% | 4680 |
|
|
2017
Q2 | $15K | Buy |
9,100
+3,300
| +57% | +$95.6K | ﹤0.01% | 3759 |
|
|
2017
Q1 | $8K | Buy |
5,800
+3,000
| +107% | +$79.1K | ﹤0.01% | 4324 |
|
|
2016
Q4 | $7K | Buy |
2,800
+1,000
| +56% | +$31.7K | ﹤0.01% | 4661 |
|
|
2016
Q3 | $2K | Buy |
+1,800
| New | +$59.6K | ﹤0.01% | 5889 |
|
Cutler Group's XLRN Position: Q4 2021 in Review
Cutler Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 71,931 shares — an estimated $12.4M sold.
Cutler Group first reported a position in XLRN in Q4 2015 and held it in 12 quarters. The position peaked at $12.4M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Cutler Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Cutler Group sold 71,931 Acceleron Pharma shares in Q4 2021, an estimated $12.4M.
- Cutler Group first reported a position in Acceleron Pharma in Q4 2015 and held it in 12 quarters.
- Cutler Group's Acceleron Pharma position peaked at $12.4M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.